Rise Nano Optics Announces Strategic Partnership with Sierra Optical Lab to Produce and Commercialize SpectraGuard™ Lenses in the United Statesadmin2026-04-21T17:44:01+00:00April 21st, 2026|Read More
Rise Nano Optics Announces FDA Class I Device Classification for SPECTRAGUARD™ Nano-Optic Lens Technologyadmin2026-03-24T18:25:27+00:00March 24th, 2026|Read More
Rise Nano Optics Appoints Erik Ritchie as Chief Commercial Officer to Lead North American Commercialization Strategyadmin2026-03-22T14:51:44+00:00March 17th, 2026|Read More
Rise Nano Optics to Commence Trading on the Canadian Securities Exchange Under The Symbol “EYE”, Today, March 12, 2026admin2026-03-22T14:49:33+00:00March 12th, 2026|Read More
Rise Nano Optics Receives Final Receipt for Prospectus and Closes RTO Transactionadmin2026-03-09T15:05:04+00:00March 9th, 2026|Read More
Rise Health Nano Optics Granted Third U.S. Patent for Breakthrough Nano-Optic Technology Advancing Preventative Vision Careadmin2025-11-11T11:57:41+00:00November 11th, 2025|Read More
Rise Health Nano Optics Achieves FDA Clearance Milestone Following Successful Biocompatibility Testing for EYEGUARD™ Lensesadmin2025-09-18T10:12:55+00:00September 17th, 2025|Read More
Rise Nano Optics Announces Breakthrough in Nanomaterials Driving Major Production Efficiency Gainsadmin2025-09-18T10:13:42+00:00September 11th, 2025|Read More
Rise Health Nano Optics Provides Corporate Update on FDA Approval Process and Product Development Milestonesadmin2025-09-18T10:15:37+00:00August 25th, 2025|Read More
